PURPOSE
Rituximab is widely used off-label as a lower-cost alternative to ocrelizumab for relapsing multiple sclerosis (MS), but comparative effectiveness and safety remain uncertain. We assessed direct head-to-head evidence and concordance between randomized and real-world findings.
METHODS
PubMed/MEDLINE, Cochrane...
Yehia Nabil, Ahmed Shaheen, Anas Mansour et al.· Multiple Sclerosis and Relat...· 0 citations
AIMS
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) help in heart failure (HF), but their benefit after acute myocardial infarction is unclear. This meta-analysis assesses their impact on mortality and heart failure hospitalization post-acute myocardial infarction (AMI) and identifies which patients benefit most....
Ahmed Elazab, Ahmed Elbataa, A. Mansour et al.· British Journal of Clinical...· 0 citations
Current evidence does not support a disease-modifying effect of melatonin in MS, and any symptomatic or biomarker benefits need confirmation in larger, well-designed trials, and high-dose melatonin may carry meaningful hepatic risk.
Yehia Nabil, A. Ghazou, S. Abodabesh et al.· Frontiers in Neurology· 0 citations
The potential clinical relevance of CSP when a high ventricular pacing burden is anticipated remains plausible but was not directly demonstrated by the available data; adequately powered randomized trials are required before routine adoption.
R. Shakeel, A. Uddin, D. Ladhani et al.· Pacing and clinical electrop...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.